StockData
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. (ACRV) stock

ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$1.56+0.13 (+9.09%)

Close on Nov 18, 2026Market cap $66.85MP/E –Yield –

Acrivon Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Acrivon Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$78.37M. For fiscal 2025 it was -$84.11M. The highest annual figure on record is -$16.18M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$84.11M–
FY2024Dec 31, 2024-$89.20M–
FY2023Dec 31, 2023-$67.10M–
FY2022Dec 31, 2022-$32.66M–
FY2021Dec 31, 2021-$16.18M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$18.67M–
Q1 FY2026Mar 31, 2026-$19.90M–
Q4 FY2025Dec 31, 2025-$20.12M–
Q3 FY2025Sep 30, 2025-$19.69M–
Q2 FY2025Jun 30, 2025-$22.65M–
Q1 FY2025Mar 31, 2025-$21.66M–
Q4 FY2024Dec 31, 2024-$24.95M–
Q3 FY2024Sep 30, 2024-$25.14M–
Q2 FY2024Jun 30, 2024-$21.44M–
Q1 FY2024Mar 31, 2024-$17.67M–
Q4 FY2023Dec 31, 2023-$21.05M–
Q3 FY2023Sep 30, 2023-$16.14M–
Q2 FY2023Jun 30, 2023-$15.52M–
Q1 FY2023Mar 31, 2023-$14.39M–
Q4 FY2022Dec 31, 2022-$9.95M–
Q3 FY2022Sep 30, 2022-$9.58M–
Q2 FY2022Jun 30, 2022-$5.93M–
Q1 FY2022Mar 31, 2022-$7.21M–
Q4 FY2021Dec 31, 2021-$4.27M–
Q3 FY2021Sep 30, 2021-$2.67M–

More Acrivon Therapeutics figures

See a number that looks wrong?